PGx Medical starts the new year with the addition of bipolar and seizure to their medication classes.
Pharamcogenetic Testing:
PGx Medical test results provide clinicians with valuable patient-specific information to make better therapeutic treatment decisions. Medications may be assessed in the following areas of clinical care: hypertension, hyperlipidemia, arrhythmia, anti-coagulation, thrombophilia, depression, psychosis, anxiety, ADHD, pain (including musculoskeletal, arthritis, migraine and neuropathic), bipolar and seizure.
With the PGx Medical Metabolic Validation Program you will receive a customized patient report which includes personalized result interpretations and actionable treatment recommendations.
By adding bipolar and seizure medications, PGx Medical now reports on 19 genes and 16 medication classes to help physicians target treatment and medications to each individual patient’s genetics. This takes away the “trial and error” process by finding a medication that works best for each person. With a simple buccal swab of the cheek, physicians will now know what medications a patient has the ability to metabolize, and which ones they don’t. Guiding them in dosing decisions and helping the patient live a better quality of life.
“We’re excited about 2016 and the enhancements to our program that we will rollout. Adding the two medication classes is just the beginning. Through our local and national partnerships, we have been able to educate and implement our Metabolic Validation Program in hundreds of homes, clinics and pharmacies across the country. We look forward to expanding our work to many more physicians and care providers who desire to increase medical efficiencies, reduce costs, and ultimately give the best care possible to each individual patient,” Clay Bullard, President, PGx Medical.
For more information or to schedule an appointment, contact:
PGx Medical
Individualized Care – Personalized Medicine
405-509-5112
info@pgxmed.com